INVESTOR RELATIONS

Overview

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
NK (Common Stock) $4.98 - 0.02 (0.40%)
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

NantKwest Announces Successful First in Human Administration of CD16 High Affinity Natural Killer (haNK) Cells

Oct 02, 2017 | Press Releases

Successful Administration Of Off The Shelf Hank Cells In Patients With Solid Tu

Read More

NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors

Sep 22, 2017 | Press Releases

CULVER CITY, Calif.--(BUSINESS WIRE)--Sep. 22, 2017-- NantKwest, Inc. (Nasdaq:N

Read More

NantKwest to Present at Upcoming Investment Conferences

Sep 05, 2017 | Press Releases

CULVER CITY, CALIFORNIA-(BUSINESS WIRE), September 5, 2017 NantKwest (Nasdaq:NK), a l

Read More

Upcoming Events
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.